Robotic Radical Cystectomy for Bladder Cancer in Lucknow: What Patients Should Know?

A diagnosis of bladder cancer, particularly muscle-invasive bladder cancer (MIBC), often brings several important questions. Does the bladder need to be removed? Can the surgery be performed robotically? Will chemotherapy be required? How will urine pass after bladder removal? And what can a patient expect after surgery?

For appropriately selected patients with muscle-invasive bladder cancer, radical cystectomy with pelvic lymph-node dissection remains an established curative treatment. Contemporary management, however, extends beyond surgery alone and may involve perioperative systemic therapy, careful selection of urinary diversion and structured postoperative surveillance.

At Uro-Onco Connect, Lucknow, bladder cancer treatment is planned from a comprehensive uro-oncology perspective, taking into account the stage and biology of the cancer, overall fitness, kidney function, previous treatment and individual patient factors.

What Is Radical Cystectomy?

Radical cystectomy is a major uro-oncological operation performed to remove the urinary bladder and associated structures when required for adequate cancer control.

In men, standard radical cystectomy generally includes removal of the bladder along with the prostate and seminal vesicles. In women, the extent of surgery is tailored according to tumour location and oncological requirements. Pelvic lymph-node dissection forms an important component of the operation.

Because the bladder normally stores urine, removing it also means that the surgeon must create a new pathway for urine to leave the body. This is known as urinary diversion.

When Is Radical Cystectomy Required for Bladder Cancer?

Radical cystectomy is most commonly considered in patients with muscle-invasive bladder cancer.

Current European Association of Urology (EAU) guidance recommends radical cystectomy for suitable patients with T2–T4a N0M0 disease. Surgery may also be considered in selected patients with very-high-risk non-muscle-invasive bladder cancer or disease that remains uncontrolled despite appropriate intravesical treatment such as BCG.

Not every patient diagnosed with bladder cancer requires bladder removal.

Treatment depends upon several factors, including:

• Stage and grade of the tumour
• Histological subtype
• Presence or absence of lymph-node or distant metastases
• Response to previous treatment
• Kidney function
• Age and overall medical fitness
• Suitability for systemic therapy
• Patient preferences and quality-of-life considerations

This makes accurate staging and multidisciplinary treatment planning particularly important before proceeding with radical cystectomy.

What Is Robotic Radical Cystectomy?

Robot-assisted radical cystectomy (RARC) allows radical cystectomy and pelvic lymph-node dissection to be performed through small abdominal incisions using a robotic surgical platform.

The robotic system does not perform the surgery independently. Every step of the procedure is controlled by the surgeon.

Robotic technology provides the operating surgeon with magnified three-dimensional vision and highly articulated instruments, facilitating precise dissection within the deep and confined spaces of the pelvis.

Importantly, the fundamental oncological objectives remain the same whether the procedure is performed robotically or through conventional open surgery:

Complete removal of the cancer, appropriate lymph-node dissection and safe reconstruction of the urinary tract.

Is Robotic Radical Cystectomy Better Than Open Radical Cystectomy?

This question requires a balanced answer.

Current evidence indicates that robotic and open radical cystectomy have broadly comparable oncological outcomes, surgical-margin outcomes and overall complication rates. Robotic surgery is associated with reduced blood loss and may offer some perioperative recovery advantages, although operating times can be longer.

Therefore, choosing between robotic and open surgery should not be based simply on the availability of a robot.

An equally important question is:

Is the operation being performed by a team experienced in radical cystectomy, pelvic lymph-node dissection and urinary reconstruction?

EAU guidance specifically emphasises surgeon and institutional experience when selecting a centre for radical cystectomy.

What Happens After the Bladder Is Removed?

Removing the bladder is only one component of radical cystectomy.

The kidneys continue producing urine, so a new pathway must be created for urine to leave the body. The appropriate urinary diversion is selected according to the patient's cancer, kidney function, anatomy, general health and preferences.

Ileal Conduit

An ileal conduit is one of the most established forms of urinary diversion.

A short segment of small intestine is isolated and connected to the ureters. Its other end is brought to the abdominal wall as a stoma, through which urine continuously drains into an external collection appliance.

For many patients, an ileal conduit provides a reliable and relatively straightforward urinary diversion following radical cystectomy.

Orthotopic Neobladder

In carefully selected patients, a reservoir can be constructed from intestine and connected to the urethra. This is called an orthotopic neobladder.

It allows urine to be passed through the natural urinary passage rather than through an abdominal stoma.

However, a neobladder is not suitable for every patient. Tumour characteristics, urethral involvement, kidney function, general fitness and the patient's ability to understand and manage the neobladder all need consideration.

Other Urinary Diversions

Other forms of urinary diversion may occasionally be appropriate, particularly when patient-related factors make a conventional ileal conduit or neobladder unsuitable.

The decision should therefore be individualised rather than choosing a diversion solely on patient age or preference.

Is Chemotherapy Required Before Radical Cystectomy?

For many patients with muscle-invasive urothelial bladder cancer, surgery should not be considered in isolation.

Cisplatin-based neoadjuvant chemotherapy before radical cystectomy has an established role in eligible patients. More recently, perioperative systemic treatment for muscle-invasive bladder cancer has evolved further, and contemporary guidelines incorporate newer systemic approaches for appropriately selected patients.

This is one reason why consultation with a uro-oncology team before surgery is important.

The treatment sequence should ideally be decided before proceeding directly to radical cystectomy so that potentially beneficial systemic treatment is not inadvertently omitted.

Can the Bladder Sometimes Be Preserved?

Yes.

Radical cystectomy is not the only curative-intent treatment strategy for every patient with muscle-invasive bladder cancer.

In appropriately selected patients, trimodality therapy combining maximal transurethral resection of the bladder tumour (TURBT), radiotherapy and concurrent radiosensitising chemotherapy can provide a bladder-preserving alternative.

Patient selection is crucial.

A specialist consultation should therefore address not only “Can my cystectomy be done robotically?” but also the more fundamental question:

“What is the most appropriate curative treatment strategy for my particular bladder cancer?”

What Is Recovery Like After Robotic Radical Cystectomy?

Even when performed robotically, radical cystectomy remains a major cancer operation.

Recovery varies according to age, general health, nutritional status, disease extent, urinary diversion and the individual postoperative course.

Modern Enhanced Recovery After Surgery (ERAS) pathways focus on several aspects of recovery, including early mobilisation, appropriate pain control, prevention of venous thromboembolism, restoration of nutrition and early education regarding urinary diversion.

Before discharge, patients and their caregivers are also taught how to manage the urinary diversion.

Follow-up subsequently includes review of the final histopathology, assessment of kidney function and metabolic health, management of the urinary diversion and appropriate oncological surveillance.

Why Does Specialised Experience Matter in Bladder Cancer Surgery?

Radical cystectomy is substantially more complex than simply removing the urinary bladder.

A typical operation may combine:

Radical cystectomy + pelvic lymph-node dissection + urinary reconstruction

within the same surgical procedure.

The operation therefore requires expertise not only in cancer removal but also in complex pelvic surgery, lymph-node dissection, bowel reconstruction and postoperative management of urinary diversion.

Current EAU recommendations recognise the importance of surgeon and institutional experience in radical cystectomy outcomes.

For this reason, patients diagnosed with muscle-invasive or complex bladder cancer may benefit from evaluation by a surgeon whose clinical practice specifically focuses on uro-oncology and complex urological cancer surgery.

Robotic Radical Cystectomy and Bladder Cancer Treatment in Lucknow

Patients diagnosed with muscle-invasive bladder cancer, recurrent high-risk bladder cancer or those who have been advised radical cystectomy can undergo specialist evaluation to determine the complete treatment pathway.

At Uro-Onco Connect, Lucknow, the objective is not to perform robotic surgery simply because robotic technology is available.

The objective is to determine:

Whether surgery is required → whether systemic therapy should precede surgery → whether robotic or open surgery is appropriate → what urinary diversion is most suitable → and what treatment or surveillance is required afterwards.

For selected patients in whom surgery is appropriate, robotic radical cystectomy with pelvic lymph-node dissection and urinary diversion can form part of a comprehensive bladder cancer treatment strategy.

About Dr. Anshuman Singh

Dr. Anshuman Singh
M.S., M.Ch. Urology (Gold Medalist)
Fellowship – Uro-Oncology & Robotic Surgery (USI, Intuitive Certified)
Visiting Fellow – Robotic Uro-Oncology, Fundació Puigvert, Spain
Clinical Observer – Robotic Pelvic Oncology, University College London Hospitals (UCLH), London

Vice Chairperson – Uro-Oncology & Robotic Surgery
Chandan Cancer Institute, Chandan Hospital
Lucknow

Dr. Anshuman Singh is a Uro-Oncology and Robotic Surgery specialist in Lucknow with dedicated training in the surgical management of urological cancers. He completed his M.Ch. in Urology with a Gold Medal, followed by a dedicated Fellowship in Uro-Oncology and Robotic Surgery, with certification from the Urological Society of India (USI) and Intuitive Surgicals U.S.A. His international exposure in robotic uro-oncology includes training as a Visiting Fellow in Robotic Uro-Oncology at Fundació Puigvert, Spain, and as a Clinical Observer in Robotic Pelvic Oncology at University College London Hospitals (UCLH), London.

He currently serves as Vice Chairperson – Uro-Oncology & Robotic Surgery at Chandan Cancer Institute, Chandan Hospital, Lucknow. His clinical practice focuses on the evaluation and surgical treatment of prostate cancer, bladder cancer, kidney cancer, testicular cancer, penile cancer and other complex urological malignancies, with particular emphasis on robot-assisted uro-oncological surgery and complex pelvic cancer surgery. Patients diagnosed with bladder cancer or those advised radical cystectomy can seek a specialist opinion regarding staging, systemic therapy, suitability for bladder preservation, robotic or open radical cystectomy, urinary diversion and postoperative surveillance.